Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs As Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone

Overview

Journal Mol Cell Proteomics

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2015 Dec 16

PMID 26667175

Citations 14

Authors

Graziella E Ronsein

Gissette Reyes-Soffer

Yi He

Michael Oda

Henry Ginsberg

Jay W Heinecke

Affiliations

Soon will be listed here.

Abstract

Low levels of high-density lipoprotein cholesterol (HDL-C) and high triglyceride levels contribute to the excess rate of cardiovascular events seen in subjects with type 2 diabetes. Fenofibrate treatment partially reverses dyslipidemia in these subjects. However, a paradoxical marked reduction in HDL-C and HDL's major protein, apolipoprotein A-I, is a complication of fenofibrate in combination with rosiglitazone, an insulin-sensitizing agent. Risk factors for this condition, termed hypoalphalipoproteinemia, have yet to be identified. Using a case-control study design with subjects enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, we tested the hypothesis that alterations in HDL's protein cargo predispose diabetic subjects to fenofibrate/rosiglitazone-induced hypoalphalipoproteinemia. HDL was isolated from blood obtained from controls (no decreases or increase in HDL-C while receiving fenofibrate/rosiglitazone therapy) and cases (developed hypoalphalipoproteinemia after fenofibrate/rosiglitazone treatment) participating in the ACCORD study before they began fenofibrate/rosiglitazone treatment. HDL proteins were quantified by targeted parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) with isotope dilution. This approach demonstrated marked increases in the relative concentrations of paraoxonase/arylesterase 1 (PON1), apolipoprotein C-II (APOC2), apolipoprotein C-I, and apolipoprotein H in the HDL of subjects who developed hypoalphalipoproteinemia. The case and control subjects did not differ significantly in baseline HDL-C levels or other traditional lipid risk factors. We used orthogonal biochemical techniques to confirm increased levels of PON1 and APOC2. Our observations suggest that an imbalance in HDL proteins predisposes diabetic subjects to develop hypoalphalipoproteinemia on fenofibrate/rosiglitazone therapy.

Citing Articles

Elevated levels of serum alpha-2-macroglobulin associate with diabetes status and incident CVD in type 1 diabetes.

Shao B, Snell-Bergeon J, de Boer I, Davidson W, Bornfeldt K, Heinecke J J Lipid Res. 2025; 66(2):100741.

PMID: 39761918 PMC: 11841089. DOI: 10.1016/j.jlr.2025.100741.

Multi-omics analysis reveals the pathogenesis of db/db mice diabetic kidney disease and the treatment mechanisms of multi-bioactive compounds combination from .

Xu Z, Xiang X, Su S, Zhu Y, Yan H, Guo S Front Pharmacol. 2022; 13:987668.

PMID: 36249745 PMC: 9557128. DOI: 10.3389/fphar.2022.987668.

HDL proteome remodeling associates with COVID-19 severity.

Junior D, Silva A, Rosa-Fernandes L, Reis L, Alexandria G, Bhosale S J Clin Lipidol. 2021; 15(6):796-804.

PMID: 34802985 PMC: 8557113. DOI: 10.1016/j.jacl.2021.10.005.

The HDL Proteome Watch: Compilation of studies leads to new insights on HDL function.

Davidson W, Shah A, Sexmith H, Gordon S Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1867(2):159072.

PMID: 34800735 PMC: 8715479. DOI: 10.1016/j.bbalip.2021.159072.

Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects.

Ronsein G, Vaisar T, Davidson W, Bornfeldt K, Probstfield J, OBrien K Arterioscler Thromb Vasc Biol. 2021; 41(8):2330-2341.

PMID: 34134520 PMC: 8295224. DOI: 10.1161/ATVBAHA.121.316278.

References

Ginsberg H, Le N, Goldberg I, Gibson J, Rubinstein A, Norum R . Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986; 78(5):1287-95. PMC: 423815. DOI: 10.1172/JCI112713. View

Taskinen M, Beltz W, Harper I, Fields R, Schonfeld G, Grundy S . Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes. 1986; 35(11):1268-77. DOI: 10.2337/diab.35.11.1268. View

Gordon D, Rifkind B . High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989; 321(19):1311-6. DOI: 10.1056/NEJM198911093211907. View

Mendez A, Oram J, Bierman E . Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem. 1991; 266(16):10104-11. View

Stamler J, Vaccaro O, Neaton J, Wentworth D . Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16(2):434-44. DOI: 10.2337/diacare.16.2.434. View

Mackness M, Arrol S, Abbott C, Durrington P . Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993; 104(1-2):129-35. DOI: 10.1016/0021-9150(93)90183-u. View

Shachter N, Ebara T, Ramakrishnan R, Steiner G, Breslow J, Ginsberg H . Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest. 1996; 98(3):846-55. PMC: 507495. DOI: 10.1172/JCI118857. View

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

Shih D, Gu L, Xia Y, Navab M, Li W, Hama S . Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998; 394(6690):284-7. DOI: 10.1038/28406. View

10.

Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G . Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem. 1999; 36 ( Pt 4):523-5. DOI: 10.1177/000456329903600420. View

11.

Lamarche B, Rashid S, Lewis G . HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta. 1999; 286(1-2):145-61. DOI: 10.1016/s0009-8981(99)00098-4. View

12.

Berbee J, van der Hoogt C, Sundararaman D, Havekes L, Rensen P . Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res. 2004; 46(2):297-306. DOI: 10.1194/jlr.M400301-JLR200. View

13.

Khersonsky O, Tawfik D . Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005; 44(16):6371-82. DOI: 10.1021/bi047440d. View

14.

Draganov D, Teiber J, Speelman A, Osawa Y, Sunahara R, La Du B . Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005; 46(6):1239-47. DOI: 10.1194/jlr.M400511-JLR200. View

15.

Shetty C, Balasubramani M, Capps N, Milles J, Ramachandran S . Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet Med. 2007; 24(1):94-7. DOI: 10.1111/j.1464-5491.2007.02029.x. View

16.

Grant R, Meigs J . Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care. 2007; 30(3):479-84. DOI: 10.2337/dc06-1961. View

17.

Vaisar T, Pennathur S, Green P, Gharib S, Hoofnagle A, Cheung M . Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007; 117(3):746-56. PMC: 1804352. DOI: 10.1172/JCI26206. View

18.

Keidar S, Guttmann H, Stam T, Fishman I, Shapira C . High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf. 2007; 16(11):1192-4. DOI: 10.1002/pds.1448. View

19.

Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B, Mackness M . Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis. 2007; 196(1):122-128. DOI: 10.1016/j.atherosclerosis.2007.03.001. View

20.

Mymin D, Dembinski T, Friesen M . Iatrogenic severe depression of high-density lipoprotein cholesterol. J Clin Pharmacol. 2009; 49(7):865-71. DOI: 10.1177/0091270009335766. View